Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Fatty acid metabolism as a possible new therapeutic approach for glioblastomas

No. 23 | 13/05/2019 | by MM/Koh

In order to gain enough energy for their rapid growth, glioblastoma cells reprogram their fatty acid metabolism. How they do this has been unclear until now. Researchers at the German Cancer Research Center in Heidelberg have now discovered that a protein called ACBP (acyl-CoA-binding protein) enhances the transport of fatty acids into the mitochondria. This provides glioblastoma cells with the necessary energy source for their rapid growth. This discovery is not only scientifically relevant, but may also offer new therapeutic approaches for an aggressive tumor with a poor prognosis.

Tissue sample from a mouse brain showing a tumor generated from human glioblastoma cells. In green, tumor cells expressing EGFP, in red the proliferation marker Ki67 and in white the astrocyte marker GFAP.
© J. Alfonso/DKFZ

Although intensive research has been carried out for a long time, glioblastoma is still one of the most dangerous of all tumors today. The life expectancy of those affected is often just one year after diagnosis.

In order to grow so aggressively and rapidly, glioblastoma cells need a great deal of energy, which they mainly obtain from an altered fatty acid metabolism. If they are deprived of this way of generating energy, the growth of cancer cells slows down.

This thought led the scientists at the German Cancer Research Center (DKFZ) to investigate the production of a cell protein called acyl-CoA-binding protein (ACBP) in mice. The researchers found that ACBP apparently controls the availability of fatty acids in the mitochondria, the "power plants of the cell". So what would happen if ACBP was switched off?

"In our mice, we succeeded in genetically switching off ACBP completely from the tumor. This led to a longer survival of the animals because the tumor had less energy at its disposal and was therefore less able to grow," says Julieta Alfonso from the DKFZ in Heidelberg, the senior author of the study.

In several preclinical models the authors of this study could now show that ACBP blockade deprives glioblastoma cells of their fatty acid supply and thus their energy source, resulting in a slower growth rate of tumor cells and, accordingly, increased survival time of the mice.

"Our study reveals a critical link between fatty acid metabolism and the aggressive growth of glioblastoma. In the future, ACBP could possibly represent a new therapeutic target for the treatment of this poorly treatable type of cancer," concludes Alfonso.

However, the scientist points out that many questions still have to be clarified: So far, there is no drug available that inhibits the activity of ACBP. Therefore, the scientists are currently unable to make any statements about the side effects of ACBP inhibition in the entire body.

Ceren Duman, Kaneschka Yaqubi, Angelika Hoffmann, Azer Aylin Acikgöz, Andrey Korshunov, Martin Bendszus, Christel Herold-Mende, Hai-Kun Liu, and Julieta Alfonso: Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation.
Cell Metabolism 2019, 10.1016/j.cmet.2019.04.004

A picture is available for download:
www.dkfz.de/de/presse/pressemitteilungen/2019/bilder/Brain-Tumor-in-mouse.jpg 
Caption: Tissue sample from a mouse brain showing a tumor generated from human glioblastoma cells. In green, tumor cells expressing EGFP, in red the proliferation marker Ki67 and in white the astrocyte marker GFAP.

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: J. Alfonso/DKFZ".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

 

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS